Page 12 - Eceptor News Today

Though it may be a surprise to the millions of people who undergo general anesthesia every year for medical procedures, the biological mechanism for how different anesthetics block consciousness is still not fully understood.

A microbial sensor that helps identify and fight bacterial infections also plays a key role in the development of blood stem cells, valuable new insight in the effort to create patient-derived blood stem cells that could eliminate the need for bone marrow transplants.

Researchers from the University of Gothenburg, in collaboration with colleagues from University of Glasgow, present data that the drug Entresto (sacubitril/valsartan) which is commonly used for the treatment of cardiac failure leads to a marked reduction in plasma Aβ ratio, a candidate blood test for Alzheimer's disease (AD).

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

Researchers identified 5-hydroxytryptamine 2A (5-HT2A) receptor (5-HT2AR) signaling pathways associated with psychedelic potential.

Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression.

A new study finds that radiation therapy (RT) suppresses a key protein called bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) and activates immune suppressive cells.

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

An effective HIV vaccine may need to prompt strong responses from immune cells called CD8+ T cells to protect people from acquiring HIV, according to a new study from researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues.

QUT scientists have discovered a promising new therapy for a deadly type of endometrial cancer that has a poor prognosis if the cancer spreads or returns after initial treatment, a plight that affects 15-20 per cent of endometrial cancer patients.